PharmAbcine to Participate in Biotechgate Digital Partnering

DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in Biotechgate Digital Partnering taking place virtually from August 30 – September 3, 2021.

Biotechgate Digital Partnering is an event that provides a platform for business development in the field of licensing and collaboration. 14 out of the top 20 big pharma companies and more than 2,700 companies from over 60 countries have participated in the past events.

During the event, PharmAbcine's business development team will hold one-on-one virtual meetings with global pharmas, biotechs, and healthcare companies to discuss potential licensing deals or collaborations for the Company's main pipelines such as olinvacimab, PMC-403, and PMC-309.

Olinvacimab, an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) fully human antibody, is the Company's leading pipeline and is undergoing multiple global clinical trials. Currently, a Phase II olinvacimab mono study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients is taking place at multiple sites in both US and Australia. Also, two Phase Ib olinvacimab and pembrolizumab combo trials in mTNBC and rGBM are still ongoing in Australia. 

PMC-403 is a novel TIE2-activating fully human antibody designed to stabilize and repair damaged blood vessels in a variety of diseases. PMC-403 is currently in development for treating AMD (Age-related Macular Degeneration), DME (Diabetic Macular Edema), and DR (Diabetic Retinopathy) which are common abnormal vascular-related eye diseases. The Company expects PMC-403 to enter global clinical trials for both ophthalmology and oncology in 2022.

PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in development for the treatment of various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). Blocking VISTA pathways activates T cells' immune responses and leads to better anti-tumor effects. PMC-309 is expected to enter a global clinical trial in 2022.

Companies can request a business development meeting by registering for the partnering event here.

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, pulmonology, to renal pathology.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state-of-the art antibody generation services.

PharmAbcine also has unique knowhow in the area of the antibody production, early drug development, and clinical development.

For additional information about PharmAbcine, visit http://www.pharmabcine.com or follow us on Youtube and Linkedin.

For licensing deals, co-development, and collaboration in research or antibody discovery inquiries, please contact:

Business Development Team
E-mail: [email protected]
Office line: +82 70 4279 5100

For investor relations and public relations inquiries, please contact:

IR/PR Team
Paul Kim, Chief Financial Officer
E-mail: [email protected] 
Office line: +82 70 4270 2632

Sungjun Park, Associate
E-mail: [email protected] 
Office line: +82 70 4270 2637

SOURCE PharmAbcine

Related Links

http://www.pharmabcine.com/